Statement from AstraZeneca:
A recent statement from AstraZeneca acknowledged the potential risk of thrombosis with thrombocytopenia syndrome (TTS) associated with its COVID-19 vaccine, Covishield. Unlike mRNA vaccines, Covishield employs a viral vector platform, using a modified chimpanzee adenovirus to deliver the COVID-19 spike protein. TTS, highlighted by the World Health Organization, emerged as an adverse event following immunization with adenovirus vector-based COVID-19 vaccines. This underscores the importance of understanding and mitigating potential risks associated with vaccination.
What is Covishield:
Covishield is a COVID-19 vaccine developed by AstraZeneca in collaboration with the University of Oxford. It is based on a viral vector platform, utilizing a modified chimpanzee adenovirus to deliver the genetic material encoding the COVID-19 spike protein into human cells. This triggers an immune response, leading to the production of antibodies against the virus. Covishield has been authorized for emergency use in many countries and is administered via intramuscular injection. It requires two doses given several weeks apart for full vaccination. Covishield has been a significant contributor to global vaccination efforts against COVID-19.